In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Merck & Co Inc (NYSE: MRK) closed at $102.27 up 1.23% from its previous closing price of $101.03. In other words, the price has increased by $1.23 from its previous closing price. On the day, 12.53 million shares were traded. MRK stock price reached its highest trading level at $103.09 during the session, while it also had its lowest trading level at $101.52.
Ratios:
For a deeper understanding of Merck & Co Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.91 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.45. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.66. In the meantime, Its Debt-to-Equity ratio is 0.80 whereas as Long-Term Debt/Eq ratio is at 0.77.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $105.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 10 ’25 when Downing Cristal N sold 7,085 shares for $87.00 per share. The transaction valued at 616,395 led to the insider holds 0 shares of the business.
CRISTAL DOWNING bought 7,085 shares of MRK for $616,395 on Nov 10 ’25. On Nov 03 ’25, another insider, Williams David Michael, who serves as the EVP,Chief Info&Digital Officer of the company, sold 8,614 shares for $83.59 each. As a result, the insider received 720,040 and left with 24,578 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRK now has a Market Capitalization of 255448285184 and an Enterprise Value of 277053440000. As of this moment, Merck’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.53, and their Forward P/E ratio for the next fiscal year is 11.58. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.97 while its Price-to-Book (P/B) ratio in mrq is 4.91. Its current Enterprise Value per Revenue stands at 4.313 whereas that against EBITDA is 8.789.
Stock Price History:
The Beta on a monthly basis for MRK is 0.31, which has changed by -0.02433604 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, MRK has reached a high of $105.84, while it has fallen to a 52-week low of $73.31. The 50-Day Moving Average of the stock is 14.34%, while the 200-Day Moving Average is calculated to be 20.76%.
Shares Statistics:
For the past three months, MRK has traded an average of 13.14M shares per day and 17383050 over the past ten days. A total of 2.49B shares are outstanding, with a floating share count of 2.48B. Insiders hold about 0.10% of the company’s shares, while institutions hold 79.80% stake in the company. Shares short for MRK as of 1763078400 were 27626151 with a Short Ratio of 2.10, compared to 1760486400 on 26700419. Therefore, it implies a Short% of Shares Outstanding of 27626151 and a Short% of Float of 1.24.
Dividends & Splits
According to the company, the forward annual dividend rate for MRK is 3.24, from 3.2 in the trailing year. Against a Trailing Annual Dividend Yield of 0.031673763. The stock’s 5-year Average Dividend Yield is 3.05. The current Payout Ratio is 46.32% for MRK, which recently paid a dividend on 2025-09-15 with an ex-dividend date of 2025-12-15. Stock splits for the company last occurred on 2021-06-03 when the company split stock in a 1048:1000 ratio.
Earnings Estimates
. The current rating of Merck & Co Inc (MRK) reflects the combined expertise of 13.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $1.65, with high estimates of $2.4 and low estimates of -$1.55.
Analysts are recommending an EPS of between $9.07 and $8.9 for the fiscal current year, implying an average EPS of $8.97. EPS for the following year is $8.8, with 18.0 analysts recommending between $10.05 and $5.25.
Revenue Estimates
A total of 13 analysts believe the company’s revenue will be $16.18B this quarter.It ranges from a high estimate of $16.39B to a low estimate of $16.02B. As of. The current estimate, Merck & Co Inc’s year-ago sales were $15.62BFor the next quarter, 13 analysts are estimating revenue of $16B. There is a high estimate of $16.38B for the next quarter, whereas the lowest estimate is $15.44B.
A total of 17 analysts have provided revenue estimates for MRK’s current fiscal year. The highest revenue estimate was $64.98B, while the lowest revenue estimate was $64.3B, resulting in an average revenue estimate of $64.76B. In the same quarter a year ago, actual revenue was $64.17BBased on 17 analysts’ estimates, the company’s revenue will be $68.24B in the next fiscal year. The high estimate is $69.69B and the low estimate is $65.92B.
